Drug profile · INN
adagrasib
KRAZATI
adagrasib (KRAZATI) is a gtpase kras inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — adagrasib
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- ORAL
- Patents
- 4
- Programs
- 5
- Data quality
- 0.84
Quick answer
adagrasib (KRAZATI) is a gtpase kras inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
GTPase KRas inhibitor
Primary target: GTPase KRas
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Recent coverage
KRAS G12C Inhibitors NSCLC: Market Analysis of Sotorasib & Adagrasib
This article delves into the market dynamics of KRAS G12C inhibitors, Sotorasib and Adagrasib, highlighting their roles in non-small cell lung cancer treatment.
Adagrasib Phase 3 Trial Results: Key Insights on KRAS G12C NSCLC
The Phase 3 trial results of Adagrasib highlight its promising efficacy in treating KRAS G12C NSCLC, offering new hope for patients with this challenging cancer.
FDA Approval KRAS G12C NSCLC: Sotorasib & Adagrasib Insights
Explore the latest insights on FDA-approved Sotorasib and Adagrasib for treating KRAS G12C NSCLC, transforming lung cancer therapy.
FDA Accelerated Approval of KRAS G12C Inhibitors in NSCLC: Sotorasib vs Adagrasib
This article delves into the FDA's accelerated approval of KRAS G12C inhibitors, Sotorasib and Adagrasib, highlighting their impact on NSCLC treatment.
Congress & event coverage
- PresentationPharma Manufacturing World
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is adagrasib?
adagrasib (KRAZATI) is a gtpase kras inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for adagrasib?
KRAZATI is a marketed brand name for adagrasib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of adagrasib?
adagrasib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.